Can Anastrozole Raise Blood Sugar Levels?

Anastrozole can shift your body’s metabolism in ways that raise blood sugar, primarily by reducing insulin sensitivity. The drug works by blocking the enzyme aromatase, which converts androgens into estrogen, and the resulting drop in circulating estrogen appears to be the key driver behind the metabolic changes. A controlled study in healthy men found that just a few weeks of anastrozole reduced the body’s ability to use insulin properly, even without any change in body weight or fat mass. For breast cancer patients taking the drug over months or years, the effect compounds into a measurably higher risk of developing type 2 diabetes.

How Anastrozole Reduces Insulin Sensitivity

The clearest direct evidence comes from a crossover trial that gave healthy young men either anastrozole or a placebo for several weeks, then measured insulin sensitivity using a hyperinsulinemic-euglycemic clamp, which is the gold-standard test for how well the body responds to insulin. During low-dose insulin infusion, the amount of glucose that had to be pumped into the bloodstream to keep levels steady was significantly lower after anastrozole treatment compared to placebo. In plain terms, their bodies were not pulling glucose out of the blood as efficiently when insulin signaled them to do so. At the same time, anastrozole cut estradiol levels by roughly 40% and modestly raised testosterone.¹

This finding is important for a couple of reasons. First, these were healthy men with no pre-existing metabolic problems, so the reduced insulin sensitivity was not a side effect layered on top of an already fragile metabolism. Second, it emerged over a short treatment window, suggesting the effect kicks in relatively quickly once estrogen levels fall. The trial also found that anastrozole did not change how much glucose the liver was producing on its own, so the problem was specifically on the uptake side: muscles and other tissues were less responsive to insulin’s signal to absorb glucose.

Why Estrogen Matters for Blood Sugar Control

Estrogen is not just a reproductive hormone. It plays a protective role in the cells of the pancreas that produce insulin, known as beta cells. Animal and cell-culture research has shown that estradiol shields beta cells from a type of cellular damage called oxidative stress, which can cause those cells to self-destruct. When researchers exposed mouse pancreatic islets to conditions that induce oxidative damage, estradiol prevented apoptosis and preserved the cells’ ability to secrete insulin. That protection was partly lost when estrogen receptor alpha was blocked, confirming it is the hormone acting through a specific receptor rather than some general chemical buffer effect.²

Further work has detailed how estrogen receptor alpha helps maintain the internal machinery of beta cells, particularly their mitochondria and the structures involved in protein folding. When that receptor is active, it helps keep the energy-producing compartments of the cell in good working order and suppresses stress signals that would otherwise push the cell toward death.³ Estrogen also promotes insulin production itself, boosting the biosynthesis of insulin through a signaling pathway that does not require the hormone to enter the cell nucleus in the classical way.⁴

So when anastrozole suppresses estrogen production, it strips away a layer of metabolic defense. The beta cells lose some of their resilience against damage, the tissues that respond to insulin become less sensitive, and the overall glucose management system runs at a disadvantage. None of this means the drug immediately causes diabetes, but it tilts the metabolic landscape in an unfavorable direction.

Diabetes Risk in Women Taking Aromatase Inhibitors

Most of the clinical data on long-term metabolic effects comes from postmenopausal women using anastrozole (or other aromatase inhibitors) as adjuvant therapy after hormone-receptor-positive breast cancer. A study comparing postmenopausal breast cancer patients on aromatase inhibitors to similar women not receiving the drugs found higher insulin resistance and differences in body fat distribution in the treated group. The investigators noted that circulating estrogen levels were lower in the treated women, while androgens were not elevated, pointing to estrogen deficiency rather than androgen excess as the likely culprit. They cited emerging observational data suggesting a greater-than-fourfold increased risk of developing diabetes associated with aromatase inhibitor therapy.⁵

A broader view comes from a 2022 meta-analysis that pooled results across multiple studies of endocrine therapy in breast cancer patients. That analysis found a roughly 30% higher risk of type 2 diabetes in patients using endocrine therapy compared to breast cancer patients who did not receive it, and about a 19% excess risk compared to matched cancer-free controls.⁶ The gap between the fourfold figure from some individual studies and the 30% excess from the meta-analysis reflects the usual spread you see when single cohorts are compared to pooled data. Some of those individual studies were quite small or focused on specific populations. The meta-analysis gives a more conservative picture of average risk across a broader group, though it still confirms that the risk is real and not trivial.

Worth noting is that not all studies reached statistical significance on their own, which is common when individual trials are small. The overall signal from combining them is more reliable than any single result, and the direction consistently points toward increased diabetes risk.

Effects in Men

Anastrozole is sometimes used off-label in men, particularly those with low testosterone who are trying to raise their levels without using exogenous testosterone. The idea is that blocking aromatase prevents the conversion of testosterone to estrogen, thereby raising testosterone while lowering estrogen. The crossover trial mentioned earlier, which tested anastrozole against placebo in healthy men, showed a clear reduction in insulin sensitivity after just weeks of use, with no accompanying change in weight or body composition.¹

This matters because men using anastrozole off-label may not be warned about metabolic side effects. The conversation usually centers on hormone levels, bone density, and mood. Blood sugar monitoring does not routinely come up. If you are a man taking anastrozole for hormonal optimization, the evidence suggests your insulin sensitivity may take a hit regardless of whether your testosterone numbers look better on paper. That tradeoff is worth discussing with whoever is prescribing the medication, especially if you already have risk factors for diabetes like excess weight, a family history, or prediabetes.

Body Weight Is Not the Explanation

A reasonable first guess is that anastrozole raises blood sugar by causing weight gain, since excess body fat is one of the strongest drivers of insulin resistance. But the data does not support that explanation. In the controlled crossover trial in men, no significant differences in weight, body mass index, or body fat percentage appeared between the anastrozole and placebo phases.⁷

A larger trial, the IBIS-II prevention trial, looked at body composition changes in women randomized to anastrozole or placebo for breast cancer prevention. Over nine to eighteen months, the anastrozole group weighed about 0.1 kg less on average and had roughly 0.1 kg more body fat and 0.3 kg less fat-free mass than the placebo group. None of these differences reached statistical significance, and the confidence intervals suggested that even if a real effect existed, it was likely less than a kilogram and therefore unlikely to be clinically meaningful.⁸

The implication is that the metabolic effects of anastrozole operate through hormonal pathways rather than through changes in body size. You do not need to gain weight for the drug to alter how your body handles glucose. This makes the effect sneakier in a practical sense. Someone whose weight stays stable on anastrozole might assume their metabolism is fine, when in reality their fasting glucose and insulin resistance could be creeping upward beneath the surface.

Cholesterol and Broader Metabolic Shifts

Blood sugar is not the only metabolic marker that can shift during anastrozole therapy. Lipid profiles also change. A 2020 analysis found that patients taking nonsteroidal aromatase inhibitors like anastrozole and letrozole had a higher cumulative incidence of lipid abnormalities, such as triglycerides or cholesterol falling outside the normal range, compared to patients taking the steroidal aromatase inhibitor exemestane.⁶ This distinction between different aromatase inhibitors is interesting because it suggests the metabolic fallout is not entirely explained by estrogen suppression alone. If it were, all aromatase inhibitors would produce similar lipid changes. The structural differences between steroidal and nonsteroidal versions may interact with metabolism in subtly different ways.

The pattern of metabolic disruption during aromatase inhibitor therapy extends beyond glucose and cholesterol individually. Clinical reviews have noted that the combination of dyslipidemia, hyperglycemia, weight gain (where it occurs), and abdominal obesity during treatment can resemble metabolic syndrome, the cluster of cardiovascular risk factors that substantially raises the chance of heart disease and stroke.⁹ For breast cancer survivors who are already navigating heart health concerns, layering metabolic syndrome risk factors on top of the treatment they need for their cancer is a clinical challenge that deserves proactive attention rather than reactive treatment after problems develop.

Leptin and Hormonal Crosstalk

One less-discussed piece of the puzzle involves leptin, a hormone produced by fat cells that helps regulate appetite and energy balance. In the crossover trial of healthy men, plasma leptin was significantly lower after anastrozole treatment compared to placebo, even though body fat did not change.⁷ Leptin does more than just suppress appetite. It has its own role in insulin signaling and glucose metabolism. Lower leptin in the absence of fat loss suggests that the hormonal environment is being reshaped in ways that go beyond simply removing estrogen from the equation.

Separately, laboratory research on breast cancer cells that survived long-term anastrozole treatment found that these resistant cells expressed higher levels of leptin and its receptors, along with activation of downstream signaling molecules.¹⁰ While that finding is about cancer cell biology rather than metabolic health, it illustrates that aromatase inhibition shakes up leptin signaling in multiple tissues and contexts. The full picture of how these hormonal shifts interact to affect blood sugar is still being mapped out, and it is probably more complex than a simple estrogen-drops-then-glucose-rises story.

Practical Monitoring on Anastrozole

If you are taking anastrozole, whether for breast cancer treatment or for off-label hormonal management, periodic blood sugar monitoring is a reasonable precaution. Fasting glucose and hemoglobin A1c (the test that reflects average blood sugar over two to three months) are the most common screening tools. Many oncologists already order routine blood work, but glucose is not always on the standard panel unless someone has flagged a metabolic concern.

You do not need to wait for a diabetes diagnosis to take action. Insulin resistance exists on a spectrum. Catching a rise in fasting glucose from, say, the mid-80s to the low 100s is an opportunity to intervene with lifestyle measures like regular aerobic exercise, which independently improves insulin sensitivity, or dietary adjustments that reduce the glycemic load of your meals. These steps will not counteract the drug’s hormonal effects entirely, but they can blunt the metabolic drift enough to keep your blood sugar in a healthier range.

Conversations with your oncologist or prescribing physician should also include whether switching to a different aromatase inhibitor makes sense. As noted, not all aromatase inhibitors produce identical metabolic effects. Whether a switch improves glucose handling specifically has not been well studied in randomized trials, but the lipid data showing differences between nonsteroidal and steroidal options suggests the metabolic profiles are not interchangeable. That said, switching carries its own tradeoffs in terms of cancer efficacy and side effects, so the decision requires individual context rather than a blanket recommendation.

Who Is Most Vulnerable

Not everyone on anastrozole will develop blood sugar problems. People who start the drug with pre-existing insulin resistance, prediabetes, obesity, polycystic ovary syndrome, or a strong family history of type 2 diabetes are working with a thinner margin of safety. For them, the added metabolic burden from estrogen suppression could be the push that tips glucose regulation from borderline to clinically elevated. Someone starting from a metabolically healthy baseline has more room before the shift matters.

Age also plays a role, though for a different reason. Most women taking anastrozole for breast cancer are postmenopausal, meaning their estrogen levels are already low compared to premenopausal women. Anastrozole pushes those already-low levels down further, toward near-undetectable concentrations. The insulin-sensitizing benefit of even the small amount of estrogen that postmenopausal women produce from peripheral aromatization is not zero, and removing it has a metabolic cost. Younger men using the drug off-label may have a larger buffer because they typically start with higher insulin sensitivity, but the crossover trial shows even they are not immune to the effect.

Duration of use matters too. The breast cancer studies observing elevated diabetes risk involve years of treatment, not weeks. A five-year course of adjuvant anastrozole is standard in many treatment protocols, which gives the metabolic effects plenty of time to accumulate. Whether the insulin sensitivity changes reverse after stopping the drug is an open question. The controlled trial in men used a relatively short treatment period, so the measured effects were likely reversible. For someone who has taken the drug for five years, the answer may be less clear, especially if they developed frank prediabetes or diabetes during treatment and the metabolic changes became self-reinforcing through beta-cell exhaustion or other pathways.

How Anastrozole Compares to Tamoxifen

Tamoxifen, the other major class of endocrine therapy for hormone-receptor-positive breast cancer, acts differently. Rather than suppressing estrogen production, it blocks the estrogen receptor in breast tissue while acting as a partial agonist in other tissues, including the liver and bones. This difference in mechanism has metabolic consequences. Some evidence suggests tamoxifen does not produce the same degree of insulin resistance that aromatase inhibitors do, and it may even have favorable effects on certain metabolic markers. The review from Nature Reviews Endocrinology notes that the type of endocrine therapy matters for diabetes risk, with aromatase inhibitors consistently showing up as the more metabolically disruptive option.⁶

For patients and clinicians weighing the two options, the metabolic profile adds one more variable to a decision already influenced by cancer stage, menopausal status, bone density, blood clot risk, and individual tolerance. The point is not that tamoxifen is metabolically benign or that anastrozole is dangerous, but that these drugs have different downstream effects beyond their intended action on breast cancer, and metabolic health deserves a seat at the table when treatment choices are being made.

1
PubMed Central. Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
2
PubMed Central. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice
3
Journal of Biological Chemistry. Estrogen receptor α protects pancreatic β-cells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress
4
PubMed. The pancreatic beta-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetes
5
PubMed Central. Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
6
PubMed Central. Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy
7
The Journal of Clinical Endocrinology & Metabolism. Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
8
PubMed Central. Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trial
9
PubMed Central. Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors
10
PubMed Central. Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages